Skip to content
Checking whether you are signed in

Boston Scientific Corporation

BSXNew York Stock ExchangeFull coverage

Price
Loading your watchlists

AI-generatedPublished Nov 1, 2026, 10:37 PM UTC

Q3 fiscal 2026 edition

A free account unlocks one dossier edition a month.

Create a free account

Already have an account? Sign in

Summary

Free to read

Boston Scientific sells single-use medical devices, from heart catheters and implants to scopes and stents, mostly to hospitals. Its two growth engines have turned: electrophysiology sales fell 5.3% and Watchman 5.9% organically in the third quarter of 2026, as rival pulsed field ablation catheters took US share and doctors referred fewer patients for left atrial appendage closure. An eight-day cyber outage in August cut about 3 points from third-quarter growth, which came in at 1.5%, but both franchises were slowing before it, and management calls 2027 the trough. Moatsight estimates revenue of about $21.1 billion over the next four quarters, roughly flat, with a recovery resting on product launches now expected in 2028.

In the full dossier

  1. Part 1In brief
  2. Part 2Business explainer
  3. Part 3Earnings
  4. Part 4Valuation and projections
  5. Part 5What changed

General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers